top of page
The Professional Network for Healthcare Experts
GSK licenses HUTCHMED cancer therapy HMPL-A830 in deal worth up to $1.295bn
The agreement gives GSK worldwide rights outside Greater China to develop and commercialise HUTCHMED's first-in-class KRAS-EGFR antibody-targeted therapy conjugate HMPL-A830.
nuaxia
4 days ago2 min read
GSK’s $10.6bn Nuvalent Deal Marks a Shift Back to Late-Stage Oncology Scale Plays
GSK has agreed to acquire Nuvalent in a $10.6bn all-cash transaction, bringing a trio of late-stage lung cancer assets into its oncology portfolio and marking one of the company’s largest strategic moves in over a decade.
nuaxia
Jun 103 min read
bottom of page